The Solute Carrier Family 2 Genes Are Potential Prognostic Biomarkers in Acute Myeloid Leukemia

Abstract

Aims: The solute carrier family 2 (SLC2) genes are comprised of 14 members which are essential for the maintenance of glucose uptake and survival of tumour cells. This study was performed to investigate the associations of SLC2 family gene expression with mortality in acute myeloid leukemia (AML). Methods: Clinical features and SLC2 family gene expression data were obtained from The Cancer Genome Atlas and Gene Expression Omnibus database. The associations between SLC2 family gene expression and clinicopathologic features were analyzed using linear regression model. Kaplan-Meier survival, univariate, multivariate survival analyses and validation analysis were performed to analyze the associations between SLC2 family gene expression and patients’ overall survival. Results: Patient mortality was positively associated with age and cytogenetic risk in AML patients. Kaplan-Meier survival analysis suggested that patients with high SLC2A5 and SLC2A10 expression showed poorer survival than those with low SLC2A5 and SLC2A10 expression. In contrast, patients with high SLC2A13 expression exhibited better prognosis than those with low SLC2A13 expression ( P < 0.05 for all cases, log rank test). Multivariate survival analysis and validation analysis confirmed that high expression of SLC2A5 and SLC2A10 and low expression of SLC2A13 were associated with increased mortality ( P = 0.00, Odd ratio [OR]:4.05, 95% Confidence Interval [CI]: 1.73-10.22; P = 0.00, OR: 3.66, 95% CI: 1.54-9.25; and P = 0.01, OR: 0.26, 95% CI: 0.09-0.68, respectively). Conclusion: SLC family gene expression, such as SLC2A5, SLC2A10 and SLC2A13, was significantly associated with prognosis of AML patients, their expression levels might become useful prognostic biomarkers in AML.

Transcriptional Profiling and Biological Pathway(s) Analysis of Type 2 Diabetes Mellitus in a Pakistani Population

“…SLC2A13 and SLC33A1 are the specific genes of interest from that family based on the IPA knowledge base. There is some information implicating them as potential prognostic biomarkers in acute myeloid leukemia [87]. Both genes were upregulated in all our study subjects (Table 3) with a clear connection to the Chronic Myeloid Leukemia Signaling pathway (Figure 2).…”

Novel prognostic genes and subclasses of acute myeloid leukemia revealed by survival analysis of gene expression data

“…We followed the methods of Lai et al and Sha et al to perform the survival analyses [ 14 , 15 ]. In brief, AML patients were grouped into two subgroups, including high and low expression groups, according to the cutoff values determined by the pROC package [ 16 ].…”

Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup

“…Careful cataloging of these genes revealed several interesting clusterspecific genes, already involved in oncogenic processes, with an inverse correlation between DNAm and gene expression. In C1 cluster -enriched in immature, ETP-ALL, co-occurring DNMT3A/IDH2 mutations and myeloid features -among genes hypomethylated and overexpressed, we identified the myeloid factors, AZU1, CSF3, the oncogenic genes EGFL7 (40), FES (41), SLC2A5 (42) involved in AML, S100A6 involved in several solid tumor types (43)(44)(45) and JDP2 (46). Similarly, we also found several other cluster-specific candidate oncogenes such as CD160 (47), CD47 (48), FOSL1 (49) in C2, MAPK8 (50)(51)(52)(53) and MYEOV (54,55) in C3, and CAPG, RGS17 (56,57), FAM83A (58), LGALS (59), NCR1 (60) and EMP1 (61) in C5.…”